A Multicenter, Double‐Blind, Phase 3 Study of the Efficacy and Safety of Anifrolumab in Myositis: Rationale and Design of the JASMINE Trial
ACR Open Rheumatology · 2026-11 · 8 (11)
DOI: 10.1002/acr2.90155 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACR Open Rheumatology, online erschienen am 19.11.2026. Verfasst von Rohit Aggarwal und 9 weiteren Autor:innen. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AstraZeneca.
Abstract (Originalsprache)
Objective
Idiopathic inflammatory myopathies (IIM) including dermatomyositis (DM) and polymyositis (PM) are a part of a larger group of rare multisystem autoimmune rheumatic disorders. Evidence suggests that type I interferon (IFN) plays a pathogenic role in IIM. Anifrolumab, a human IgG 1 κ monoclonal antibody approved for treatment of moderate‐to‐severe systemic lupus erythematosus, is a type I IFN receptor antagonist that blocks downstream type I IFN signaling and induction of the type I IFN gene signature. JASMINE (NCT06455449) is a randomized, double‐blind, placebo‐controlled, phase 3 study, evaluating the efficacy and safety of subcutaneous (SC) anifrolumab versus placebo plus standard therapy in adults with DM or PM.
Methods
Adults with active, moderate to severe, “probable” or “definite” DM or PM, receiving standard therapy (oral glucocorticoids [OGC] and/or immunosuppressants) will be randomized 1:1 to receive either anifrolumab SC (n = 120) or placebo (n = 120) weekly for 52 weeks. Patients still receiving study drug (anifrolumab SC or placebo) at week 52 will rollover to an open‐label treatment period and receive anifrolumab SC weekly for an additional 52 weeks. The primary endpoint is at least a moderate improvement in disease activity, defined as a Total Improvement Score ≥40, at week 52. Key secondary endpoints evaluated at week 52 include change in muscle strength, OGC dose reduction, and moderate improvement in disease activity in the DM and PM subgroups.
Conclusion
This study aims to add to the growing body of evidence for anifrolumab use in rare multisystem autoimmune rheumatic disorders.
Förderung
- AstraZeneca
Zitieren
APA
Aggarwal, R., Chinoy, H., Lundberg, I. E., Kuwana, M., Vleugels, R. A., Anzilotti, C., Beaton, A., Cummings, C., Luu, T., & Benghoul, M. (2026). A Multicenter, Double‐Blind, Phase 3 Study of the Efficacy and Safety of Anifrolumab in Myositis: Rationale and Design of the JASMINE Trial. ACR Open Rheumatology, 8(11). https://doi.org/10.1002/acr2.90155
Vancouver
Aggarwal R, Chinoy H, Lundberg IE, Kuwana M, Vleugels RA, Anzilotti C, et al. A Multicenter, Double‐Blind, Phase 3 Study of the Efficacy and Safety of Anifrolumab in Myositis: Rationale and Design of the JASMINE Trial. ACR Open Rheumatology. 2026;8(11). doi:10.1002/acr2.90155
BibTeX
@article{Aggarwal2026,
author = {Aggarwal, Rohit and Chinoy, Hector and Lundberg, Ingrid E. and Kuwana, Masataka and Vleugels, Ruth Ann and Anzilotti, Consuelo and Beaton, Andrew and Cummings, Celeste and Luu, Tina and Benghoul, Maroua},
title = {A Multicenter, Double‐Blind, Phase 3 Study of the Efficacy and Safety of Anifrolumab in Myositis: Rationale and Design of the JASMINE Trial},
journal = {ACR Open Rheumatology},
year = {2026},
volume = {8},
number = {11},
doi = {10.1002/acr2.90155}
}
EUVIMED